A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This study will determine the efficacy and safety of RO4917838 in patients with schizophrenia
who are stable on current antipsychotic treatment (olanzapine, que tiapine, risperidone,
paliperidone or aripiprazole) with prominent negative or d isorganized thought symptoms.
After a 4 week run in period on their current anti psychotic treatment, patients will be
randomized to receive placebo 10mg, 30mg, or 60mg of RO4917838 once daily, p.o., as add-on
therapy. The anticipated time o n study treatment is <3 months, and the target sample size is
100-500 individual s.